drugset

drugset / Trial / NCT07439653

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653 ↗

Phase 1/2 Recruiting 155 enrolled TORL Biotherapeutics, LLC

Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Timeline

Start: 2026-03-31
Primary completion: 2029-03-31
Completion: 2029-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TORL-5-700	Unknown	—	—

Indications